[ CAS No. 4530-18-1 ] {[proInfo.proName]}

Name: 4530-18-1|2-((tert-Butoxycarbonyl)amino)-3-phenylpropanoic acid|98%
Brand: Ambeed
SKU: A205783
Rating: 98 (40 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 4530-18-1 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 4530-18-1 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 4530-18-1 ]

SDS Specification

Alternatived Products of [ 4530-18-1 ]

Product Details of [ 4530-18-1 ]

CAS No. :	4530-18-1	MDL No. :	MFCD00558969
Formula :	C₁₄H₁₉NO₄	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	ZYJPUMXJBDHSIF-UHFFFAOYSA-N
M.W :	265.31	Pubchem ID :	269698
Synonyms :		Chemical Name :	2-((tert-Butoxycarbonyl)amino)-3-phenylpropanoic acid

Calculated chemistry of [ 4530-18-1 ]

Physicochemical Properties

Num. heavy atoms :	19
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.43
Num. rotatable bonds :	7
Num. H-bond acceptors :	4.0
Num. H-bond donors :	2.0
Molar Refractivity :	71.34
TPSA :	75.63 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.27 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.27
Log Po/w (XLOGP3) :	2.32
Log Po/w (WLOGP) :	2.21
Log Po/w (MLOGP) :	1.96
Log Po/w (SILICOS-IT) :	1.63
Consensus Log Po/w :	2.08

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-2.72
Solubility :	0.508 mg/ml ; 0.00191 mol/l
Class :	Soluble
Log S (Ali) :	-3.55
Solubility :	0.0753 mg/ml ; 0.000284 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-3.18
Solubility :	0.176 mg/ml ; 0.000664 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	2.68

Safety of [ 4530-18-1 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P301+P312-P302+P352-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 4530-18-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 4530-18-1 ]
Downstream synthetic route of [ 4530-18-1 ]

[ 4530-18-1 ] Synthesis Path-Upstream 1~11

1
[ 150-30-1 ]
[ 24424-99-5 ]
[ 4530-18-1 ]

Yield	Reaction Conditions	Operation in experiment
81%	With sodium hydroxide In 1,4-dioxane; water at 0 - 20℃; for 5 h;	Phenylalanine (12) (1 g, 6.05 mmol) was suspended in Dioxane (15 mL) and NaOH (2M aqueous solution; 3.63 mL, 7.26 mmol) at 0 °C and to that was added (Boc)₂O (1.546 mL, 6.66 mmol) drop-wise with constant stirring. Reaction mixture was stirred at room temperature for 5 h. The reaction mixture was then concentrated under vacuum. Water (30 mL) was added and the pH of the mixture was adjusted to 3 by drop wise addition of cold 1.5 N HCl solutions. The aqueous layer was extracted with ethyl acetate (3 x 50 mL) and the organic layer was then washed with brine solution (2 x 50 mL). Combined organic layer was dried over anhydrous sodium sulphate and concentrated to give the product (tert-butoxycarbonyl)-phenylalanine (13) (1.3 g, 4.90 mmol, 81 percent yield) as gummy liquid. ¹H NMR (400 MHz, DMSO-d₆): δ 12.6 (br-s, 1H), 7.32-7.26 (m, 5H), 7.10-6.95 (br-s, 1H), 4.12-4.00 (m, 1H), 3.05-2.92 (m, 1H), 3.87-2.75 (m, 1H), 1.31 (s, 9H). MS (ESI): 266.2 as [M+H]⁺in +Ve mode.

Reference： [1] European Journal of Organic Chemistry, 2004, # 19, p. 4048 - 4059
[2] Patent: WO2004/22534, 2004, A1, . Location in patent: Page 46
[3] Tetrahedron Letters, 2018, p. 4267 - 4271
[4] Bulletin of the Korean Chemical Society, 2010, vol. 31, # 6, p. 1551 - 1554
[5] Angewandte Chemie - International Edition, 2013, vol. 52, # 49, p. 12942 - 12945[6] Angew. Chem., 2013, vol. 125, # 49, p. 13180 - 13183,4
[7] European Journal of Medicinal Chemistry, 2018, vol. 145, p. 140 - 153

2
[ 909114-65-4 ]
[ 150-30-1 ]
[ 4530-18-1 ]

Reference： [1] Synthesis, 2006, # 12, p. 1931 - 1933

3
[ 150-30-1 ]
[ 89037-64-9 ]
[ 4530-18-1 ]

Reference： [1] Journal of the Chemical Society, Chemical Communications, 1983, # 22, p. 1357 - 1358

4
[ 75-65-0 ]
[ 4530-18-1 ]
[ 180605-35-0 ]
[ 116400-16-9 ]

Reference： [1] Organic Letters, 2008, vol. 10, # 15, p. 3191 - 3194

5
[ 13734-34-4 ]
[ 4530-18-1 ]

Reference： [1] Organic Letters, 2015, vol. 17, # 14, p. 3454 - 3457

6
[ 150-30-1 ]
[ 13303-10-1 ]
[ 4530-18-1 ]

Reference： [1] Journal of the American Chemical Society, 1957, vol. 79, p. 6180,6181

7
[ 4316-58-9 ]
[ 126686-59-7 ]
[ 4530-18-1 ]

Reference： [1] Angewandte Chemie, 1982, vol. 94, # 10, p. 785

8
[ 4530-20-5 ]
[ 100-39-0 ]
[ 4530-18-1 ]

Reference： [1] Tetrahedron Letters, 1992, vol. 33, # 43, p. 6461 - 6464

9
[ 4530-18-1 ]
[ 541-41-3 ]
[ 145149-48-0 ]

Reference： [1] Patent: US2006/46978, 2006, A1, . Location in patent: Page/Page column 12

10
[ 4530-18-1 ]
[ 145149-48-0 ]

Reference： [1] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 3, p. 989 - 994
[2] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 1, p. 192 - 202

11
[ 4530-18-1 ]
[ 37736-82-6 ]

Reference： [1] Patent: US4495178, 1985, A,
[2] Patent: US4603121, 1986, A,

[ 4530-18-1 ] Synthesis Path-Downstream 1~88

2
[ 4530-18-1 ]
[ 543-27-1 ]
C₁₉H₂₇NO₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 4-methyl-morpholine; In tetrahydrofuran; dichloromethane; at -15℃; for 1h;Inert atmosphere;	General procedure: A stirred solution of N-alpha-protected amino acids 1a-f (10.58 mmol) and N-methylmorpholine (11.66 mmol) in anhydrous THF (16 mL) was cooled to -15 C under nitrogen atmosphere, before the very slow addition of isobutyl chloroformate (11.86 mmol) in anhydrous DCM (5.3 mL). After 1 h of stirring, a solution of N-benzyl-tert-butyl-beta-aminoesters 2 (10.58 mmol) and N-methylmorpholine (12.65 mmol) in anhydrous DCM was added slowly. The mixture was stirred for two additional hours at -15 C and then was allowed to warm to room temperature, and stirring was continued for 18 h. The solvent was removed under vacuum and ethyl acetate (30 mL) was added to the residue. The resulting solution was washed sequentially with water, 1 N HCl, water, saturated solution of NaHCO3, and water. The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. In order to have a complete analysis of the physical and spectroscopic properties of the chiral dipeptides it was decided to prepare both enantiomers and also the racemic mixture to serve as chiral HPLC standards.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1999,vol. 9,p. 463 - 468
[2]Tetrahedron,2010,vol. 66,p. 128 - 133
[3]Tetrahedron,2012,vol. 68,p. 9842 - 9852,11

3
[ 4530-18-1 ]
[ 16182-04-0 ]
tert-butyl 5-benzyl-4-oxo-2-thioxoimidazolidine-1-carboxylate [ No CAS ]

Reference： [1]Chemistry - A European Journal,2018,vol. 24,p. 7217 - 7227
[2]Analytical Chemistry,2000,vol. 72,p. 1389 - 1399

4
[ 4530-18-1 ]
[ 1460-16-8 ]
[ 103-71-9 ]
C₄₇H₅₄N₆O₃ [ No CAS ]

Reference： [1]Tetrahedron Letters,2000,vol. 41,p. 5441 - 5446

5
[ 4530-18-1 ]
resin-CH₂N=C(OCH₃)NH-cHex [ No CAS ]
[ 51987-73-6 ]

Reference： [1]Organic Letters,2002,vol. 4,p. 2961 - 2963

6
[ 4530-18-1 ]
[ 55536-65-7 ]
N-(N'-tert-butoxycarbonyl)phenylalanyl-3,4-dibenzyloxyphenylethylamine [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2003,vol. 1,p. 767 - 771

7
[ 4530-18-1 ]
[ 1139-83-9 ]
3-O-(N-(t-butoxycarbonyl)phenylalanyl)-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-6-one [ No CAS ]

Reference： [1]Chemistry of Natural Compounds,2002,vol. 38,p. 416 - 423

8
[ 4530-18-1 ]
[ 536-74-3 ]
2-tert-Butoxycarbonylamino-3-phenyl-propionic acid (1E,3E)-1,4-diphenyl-buta-1,3-dienyl ester [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2003,vol. 125,p. 11964 - 11975

9
[ 4530-18-1 ]
[ 29833-32-7 ]
[ 805230-93-7 ]

Reference： [1]European Journal of Organic Chemistry,2004,p. 4048 - 4059

10
[ 150-30-1 ]
[ 24424-99-5 ]
[ 4530-18-1 ]

Yield	Reaction Conditions	Operation in experiment
91%	With tetramethyl ammoniumhydroxide;	[1- [TERT-BUTOXYCARBONYL) AMINO]-1- (BENZYL)] acetic acid was isolated as a white solid (1.46g, 91%) from DL-phenylalanine (1. 0g, 6. [05MOL),] [TETRAMETHYLAMMONIUM] hydroxide (1. [01G,] 6. [05MMOL)] and [(BOC)] 20 (2.78mL, 12. [1 MMOL).]
81%	With sodium hydroxide; In 1,4-dioxane; water; at 0 - 20℃; for 5h;	Phenylalanine (12) (1 g, 6.05 mmol) was suspended in Dioxane (15 mL) and NaOH (2M aqueous solution; 3.63 mL, 7.26 mmol) at 0 C and to that was added (Boc)2O (1.546 mL, 6.66 mmol) drop-wise with constant stirring. Reaction mixture was stirred at room temperature for 5 h. The reaction mixture was then concentrated under vacuum. Water (30 mL) was added and the pH of the mixture was adjusted to 3 by drop wise addition of cold 1.5 N HCl solutions. The aqueous layer was extracted with ethyl acetate (3 x 50 mL) and the organic layer was then washed with brine solution (2 x 50 mL). Combined organic layer was dried over anhydrous sodium sulphate and concentrated to give the product (tert-butoxycarbonyl)-phenylalanine (13) (1.3 g, 4.90 mmol, 81 % yield) as gummy liquid. 1H NMR (400 MHz, DMSO-d6): delta 12.6 (br-s, 1H), 7.32-7.26 (m, 5H), 7.10-6.95 (br-s, 1H), 4.12-4.00 (m, 1H), 3.05-2.92 (m, 1H), 3.87-2.75 (m, 1H), 1.31 (s, 9H). MS (ESI): 266.2 as [M+H]+ in +Ve mode.
	With sodium hydroxide; In 1,4-dioxane; water; at 20℃; for 1h;Cooling with ice;	General procedure: Amino group of amino acids (4-6) was protected with Boc group by following procedure: The solution of amino acid (4-6) in 75mL of dioxane, 40mL of H2O and 408mL solution of IM NaOH was stirred and cooled in an ice bath. (BOC)2O (9g, 41.14mmol) was added to solution and stirred for 1h at room temperature. The solution was concentrated under vacuum to about 30-40mL. Cooled in an ice water bath, covered with layer of ethyl acetate (25mL) and acidified with dilute solution of KHSO4 to pH 2-3. The aqueous layer was extracted with ethyl acetate and washed with distilled H2O, brine and dried over MgSO4. The solvent was removed under reduced pressure and residue was chromatographed on a silica gel column using methanol 2% solution in chloroform as an eluent to afford pure product in 82% yield.

	With sodium hydroxide; In tetrahydrofuran; water; at 0 - 20℃;	General procedure: Glycine (150 mg, 2 mmol), in a solution of THF (30mL), H2O (20 mL) and NaOH (1 mol/L, 20 mL) was stirredat 0-5 for 15 min. The reaction mixture was treated with (Boc)2O (0.87 g, 4 mmol) at room temperature for overnight. The organic solvent was removed under reduced pressure. The residue was extracted by ether (50.0 mL×2). The water phase was adjusted with 1.0 mol/L HCl to pH 2-3 and then extracted with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous MgSO4 and concentrated under reduced pressure to afford N-Boc-Glycine (319.50 mg, yield 91.1%). The reaction of N-Boc-Glycine (143.65 mg, 0.82 mmol) with compound 2 (0.1 g,0.42 mmol) in the presence of EDC·HCl (0.243 g, 1.3 mmol) and Et3N (263 mg, 2.6 mmol) in CHCl3 (15mL) for 8h yielded the corresponding compound III1 (139.07 mg,85.3%). Compound III1 (139.07 mg, 0.36 mmol) was hydrolyzed using TFA (6.79 mmol) in CH2Cl2 (20 mL) at room temperature for 48h. The reaction mixture was alkalized to pH= 10 with anhydrous Na2CO3, and the CH2Cl2 layer was washed to pH 6-7 with distilled water and concentrated to dryness. The crude product was purified by column chromatography (silica gel, CHCl3-MeOH (50:1,v/v)) to give target compound IV1 as a white solid (24.66mg, yield 21.2%) Yield: 25.0%
	With sodium hydroxide; In 1,4-dioxane; water; for 1h;	General procedure: Amino acid (4.3 g, 37.4 mmol) wasdissolved in dioxane (75 mL) and after 30 min 1 MNaOH (38 mL) and H2O (38 mL) were added followedby (Boc)2O (9 g, 41.4 mmol). The reaction mixture wasstirred for 1 h and concentrated under reduced pressureto about 30-40 mL, after which ice and a little of ethylacetate. A dilute KHSO4 solution was then added verycarefully to the reaction mixture to adjust its pH to 2-3.The solution was then washed with brine and the productwas extracted with ethyl acetate and dried over MgSO4.The solvent was evaporated under reduced pressure.

Reference： [1]European Journal of Organic Chemistry,2004,p. 4048 - 4059
[2]Patent: WO2004/22534,2004,A1 .Location in patent: Page 46
[3]Tetrahedron Letters,2018,p. 4267 - 4271
[4]Bulletin of the Korean Chemical Society,2010,vol. 31,p. 1551 - 1554
[5]Angewandte Chemie - International Edition,2013,vol. 52,p. 12942 - 12945
Angew. Chem.,2013,vol. 125,p. 13180 - 13183,4
[6]European Journal of Medicinal Chemistry,2018,vol. 145,p. 140 - 153
[7]Letters in drug design and discovery,2019,vol. 16,p. 663 - 669
[8]Russian Journal of Organic Chemistry,2020,vol. 56,p. 292 - 297

11
(±)-tert-butyl-2-[(tert-butoxycarbonyl)amino]phenylpropionate [ No CAS ]
[ 4530-18-1 ]

Reference： [1]Journal of Organic Chemistry,2005,vol. 70,p. 3737 - 3740

12
[ 4530-18-1 ]
[ 6938-68-7 ]
C₁₆H₂₄N₄O₃S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 3749 - 3757

13
[ 4530-18-1 ]
3-(benzyloxyamino)propanoic acid ethyl ester [ No CAS ]
3-[benzyloxy-(2-<i>tert</i>-butoxycarbonylamino-3-phenyl-propionyl)-amino]-propionic acid ethyl ester [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2002,vol. 124,p. 12666 - 12667

14
[ 4530-18-1 ]
[ 107-18-6 ]
allyl 2-(tert-butoxycarbonylamino)-3-phenylpropanoate [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2009,vol. 74,p. 3406 - 3413
[2]Journal of the American Chemical Society,2006,vol. 128,p. 10002 - 10003

15
[ 4795-29-3 ]
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 19125-34-9 ]
3-benzyl-9-phenyl-1-(tetrahydro-furan-2-ylmethyl)-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4145 - 4152

16
Rink-isonitrile resin [ No CAS ]
[ 1445-73-4 ]
[ 4530-18-1 ]
[ 18471-40-4 ]
3-benzyl-1-(1-benzyl-pyrrolidin-3-yl)-9-methyl-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4145 - 4152

17
Rink-isonitrile resin [ No CAS ]
[ 1445-73-4 ]
[ 4530-18-1 ]
[ 100-46-9 ]
1,3-dibenzyl-9-methyl-1,4,9-triazaspiro[5.5]undeca-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

18
methylene-isonitrile resin [ No CAS ]
[ 1445-73-4 ]
[ 4530-18-1 ]
[ 100-46-9 ]
1,3-dibenzyl-9-methyl-1,4,9-triazaspiro[5.5]undeca-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

19
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 61-54-1 ]
[ 19125-34-9 ]
3-benzyl-1-[2-(1<i>H</i>-indol-3-yl)-ethyl]-9-phenyl-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4145 - 4152

20
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 3612-20-2 ]
[ 18471-40-4 ]
3,9-dibenzyl-1-(1-benzyl-pyrrolidin-3-yl)-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

21
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 3612-20-2 ]
[ 100-46-9 ]
1,3,9-tribenzyl-1,4,9-triazaspiro[5.5]undeca-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

22
methylene-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 3612-20-2 ]
[ 100-46-9 ]
1,3,9-tribenzyl-1,4,9-triazaspiro[5.5]undeca-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

23
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 39742-60-4 ]
[ 18471-40-4 ]
3-benzyl-1-(1-benzyl-pyrrolidin-3-yl)-9-phenethyl-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

24
Rink-isonitrile resin [ No CAS ]
[ 107-10-8 ]
[ 4530-18-1 ]
[ 19125-34-9 ]
3-benzyl-9-phenyl-1-propyl-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4145 - 4152

25
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 19125-34-9 ]
[ 3963-62-0 ]
3-benzyl-1-(2,2-diphenyl-ethyl)-9-phenyl-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4145 - 4152

26
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 19125-34-9 ]
[ 18471-40-4 ]
3-benzyl-1-(1-benzyl-pyrrolidin-3-yl)-9-phenyl-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4145 - 4152

27
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 107100-64-1 ]
[ 18471-40-4 ]
3-benzyl-1-(1-benzyl-pyrrolidin-3-yl)-9-(3-phenyl-propyl)-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

28
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 109807-95-6 ]
[ 18471-40-4 ]
3-benzyl-1-(1-benzyl-pyrrolidin-3-yl)-9-(4-phenyl-butyl)-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

29
1-(6-phenylhexyl)-4-piperidone [ No CAS ]
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 18471-40-4 ]
3-benzyl-1-(1-benzyl-pyrrolidin-3-yl)-9-(6-phenyl-hexyl)-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

30
Rink-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 18471-40-4 ]
[ 905721-52-0 ]
3-benzyl-1-(1-benzyl-pyrrolidin-3-yl)-9-(5-phenyl-pentyl)-1,4,9-triaza-spiro[5.5]undecane-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

31
methylene-isonitrile resin [ No CAS ]
[ 4530-18-1 ]
[ 100-46-9 ]
[ 905721-52-0 ]
1,3-dibenzyl-9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undeca-2,5-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 4140 - 4152

32
[ 4530-18-1 ]
[ 4822-44-0 ]
(+/-)-2-tert-butoxycarbonylamino-3-phenyl-thiopropionic acid phenylcarbamoyl methyl ester [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2007,vol. 129,p. 1132 - 1140

33
[ 909114-65-4 ]
[ 150-30-1 ]
[ 4530-18-1 ]

Reference： [1]Synthesis,2006,p. 1931 - 1933

34
[ 4530-18-1 ]
[ 146563-40-8 ]
4-nitrooxy-butyl 2-tert-butoxycarbonylamino-3-phenyl-propanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 1,8-diazabicyclo[5.4.0]undec-7-ene; potassium iodide; In dichloromethane; acetone; at 20℃; for 4h;	N) BOC-omophenylalanine 4-(nitrooxy)butyl ester; To a solution of BOC-omophenylalanine (1 g, 3.58 mmol) in acetone (50 ml) compound M) (8.43 g, 25% w/w in methylene chloride, 7.16 mmol), DBU (1.36 g, 8.95.3 mmol) and Kl (0.59 g, 3.58 mmol) were added and the reaction was stirred at room temperature for 4 hours. The solution was washed with water and the organic layers were dried with sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography, eluent ethyl acetate. The product (1 g) was obtained.

Reference： [1]Patent: WO2007/641,2007,A2 .Location in patent: Page/Page column 59

35
[ 4530-18-1 ]
N-(diphenylmethylene)-1,4-diphenylpent-4-en-2-amine [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2006,vol. 128,p. 10002 - 10003

36
[ 4530-18-1 ]
[ 88815-83-2 ]

Reference： [1]Journal of Organic Chemistry,2014,vol. 79,p. 3765 - 3775
[2]Tetrahedron,1999,vol. 55,p. 10437 - 10446

37
[ 4530-18-1 ]
[ 38427-90-6 ]

Reference： [1]Organic Letters,2014,vol. 16,p. 4228 - 4231
[2]Synlett,1997,vol. 1997,p. 181 - 182

38
[ 4530-18-1 ]
floxuridine [ No CAS ]
C₂₃H₃₀FN₃O₈ [ No CAS ]
C₂₃H₃₀FN₃O₈ [ No CAS ]
C₃₇H₄₇FN₄O₁₁ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With dicyclohexyl-carbodiimide; 4-amino-2,3-dimethylpyridine; In DMF (N,N-dimethyl-formamide); at 20℃; for 48h;	The 3'-monoester, 5'-monoester, and 3',5'-diester prodrugs of floxuridine are synthesized as follows: N-t-Boc-amino acid (1.8 mmole), dimethyl-pyrindin-4-yl-amine (0.19 mmole) and dicyclohexyl carbodiimide (2.17 mmole) are added to floxuridine (1.33 mmole) in dry dimethylformamide (DMF) (30 ml). The solution is stirred under a nitrogen atmosphere at ambient temperature for 48 hrs and then the mixture is filtered. The DMF is removed from the filtrate in vacuo and the residue is chromatographed on silica gel, using CH3OH/CH2Cl2 (1:4) as the eluant.

Reference： [1]Patent: US2005/137141,2005,A1 .Location in patent: Page/Page column 5

39
[ 4530-18-1 ]
[ 541-41-3 ]
[ 145149-48-0 ]

Yield	Reaction Conditions	Operation in experiment
		N-(tert-butoxycarbonyl)-DL-phenylalanine (10 g, 37.7 mmol) was dissolved in THF (38 ml) and cooled to 0 C. Then triethylamine (5.8 ml, 41.5 mmol) and ethyl chloroformate (4 ml, 41.5 mmol) were added and stirred for 1 h at 0 C. The solution was filtered, cooled to 0 C. and a solution of sodium borohydride (1.4 g, 57 mmol) in water (15 ml) was slowly added. After stirring for 30 min at 0 C., the solution was warmed to rt and stirred over night. The reaction mixture was acidified with 1 N HCl and extracted several times with ethyl acetate. The combined organic layers were washed with sat. bicarbonate and brine, dried over MgSO4, filtered and evaporated. 1H-NMR (300 MHz, CDCl3) 7.33-7.21 (m, 5H), 4.9 (bs, 1H), 3.87 (bs, 1H), 3.68-3.52 (m, 2H), 2.87-2.84 (m, 3H), 1.42 (s, 9H)

Reference： [1]Patent: US2006/46978,2006,A1 .Location in patent: Page/Page column 12

40
[ 4530-18-1 ]
[ 2577-90-4 ]
[ 3945-69-5 ]
[ 13122-89-9 ]

Yield	Reaction Conditions	Operation in experiment
95.0%	In dichloromethane; water;	Example 100 Into a 100-ml egg plant-type flask were added 2.65 g (0.01 mol) of an N-tert-butoxycarbonylphenylalanine, 1.79 g (0.01 mmol) of a Phenylalaninemethyl ester and 25 ml of a dichloromethane, which were then stirred at room temperature for 10 minutes. Next, into a 200-ml egg plant-type flask were added 27.3 g of the same <strong>[3945-69-5]4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride</strong> (water content of 8.4% by weight and purity of 99.5%) as the one obtained in Example 1 and 72.7 g of water, which were stirred and dissolved at 20 C. to separately prepare the condensing agent of the invention. 11.08 Grams (0.01 mol) of the thus prepared condensing agent of the invention was slowly added to the above 100-ml egg plant-type flask to effect the reaction at room temperature for 3 hours. After the reaction, 25 ml of a dichloromethane was added thereto, and the mixture was washed with 50 ml of water to separate the organic layer which was then dried on magnesium sulfate, condensed and was isolated and refined by using a silica gel column chromatography to obtain 4.05 g of an N-tert-butoxycarbonyl-L-phenylalanyl-L-phenylalaninemethyl ester (yield, 95.0%).

Reference： [1]Patent: US2003/153785,2003,A1

41
[ 4530-18-1 ]
[ 74-88-4 ]
[ 51987-73-6 ]

Yield	Reaction Conditions	Operation in experiment
13.6 g (96%)	With potassium hydrogencarbonate; In water; N,N-dimethyl-formamide;	(1) To a mixture of N-tert-butoxycarbonylphenylalanine (13.3 g, 50.0 mmol), potassium hydrogencarbonate (10.0 g, 100 mmol) and N,N-dimethylformamide (80 mL) was added methyl iodide (5 mL, 80 mmol). The resulting mixture was stirred at room temperature for 5 h, and water (200 mL) was added. The mixture was extracted with ethyl acetate-benzene (1:1), and the organic layer was washed successively with water, 5% aqueous sodium sulfite solution and saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated and the obtained residue was separated and purified by silica gel column chromatography (hexane-ethyl acetate, 90:10) to give 13.6 g (96%) of N-tert-butoxycarbonylphenylalanine methyl ester as a colorless oil.

Reference： [1]Patent: US5948785,1999,A
[2]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 989 - 994

42
[ 4530-18-1 ]
[ 30566-31-5 ]
[ 51987-73-6 ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; triethylamine; In dichloromethane;	14-1) Preparation of N-t-butoxycarbonyl-L-phenylalanine methyl ester To a solution of 8.8 g(0.0344 mol) of N-t-butoxycarbonylphenylalanine in 50 ml of dichloromethane were successively added 5.25 ml of triethylamine solution, and 3 ml of chloromethylformate at 0 C. 50 mg of 4-dimethylaminopyridine was added to catalyze the reaction. After the reaction was completed the reaction mixture was extracted with dichloromethane and distilled under a reduced pressure to give the title compound quantitatively. 1 H NMR(CDCl3) delta1.4(9H, s), 3.1(2H, m), 3.7(3H, s), 4.6(1H, m), 5.0(1H, d), 7.1-7.3(5H, m)
	With dmap; triethylamine; In dichloromethane;	14-1) Preparation of N- t -butoxycarbonyl-L-phenylalanine methyl ester To a solution of 8.8g(0.0344mol) of N- t -butoxycarbonylphenylalanine in 50ml of dichloromethane were successively added 5.25ml of triethylamine solution, and 3ml of chloromethylformate at 0C. 50mg of 4-dimethylaminopyridine was added to catalyze the reaction. After the reaction was completed the reaction mixture was extracted with dichloromethane and distilled under a reduced pressure to give the title compound quantitatively. 1H NMR(CDCl3) delta 1.4(9H, s), 3.1(2H, m), 3.7(3H, s), 4.6(1H, m), 5.0(1H, d), 7.1-7.3(5H, m)

Reference： [1]Patent: US5587388,1996,A
[2]Patent: EP601486,1994,A1

43
[ 4530-18-1 ]
[ 37736-82-6 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogen;rhodium; In tetrahydrofuran;	EXAMPLE 36 t-butoxycarbonyl-3-cyclohexyl-L-alanine A solution of 30.0 g (0.11 mole) of t-butoxycarbonylphenylalanine in 750 ml of tetrahydrofuran was hydrogenated at 60 for 24 hours using 50 psi hydrogen gas and 5% rhodium on carbon. The mixture was filtered and the filtrate concentrated to give the title compound (30.7 g) as a colorless oil. The oil was used without further purification. Structure assignment was supported by the nmr spectrum (loss of aromatic protons and appearance of cyclohexyl protons).

Reference： [1]Patent: US4495178,1985,A

44
[ 4530-18-1 ]
[ 223747-23-7 ]
2-benzyloxy-3,10-dimethoxy-9-(N-t-Boc-phenylalanyloxy)-12-chloro-5,8,13,13a-tetrahydro-6H-dibenzo[a,g]quinolizine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
93.3%	With dicyclohexyl-carbodiimide; In dichloromethane; at 20℃; for 6h;Product distribution / selectivity;	Compound IIA (0.5 g, 1.1 mmol) was dissolved in CH2Cl2 (20 ml), adding t-Boc-phenylanine (0.88 g, 3.3 mmol) and DCC (0.91 g, 4.4 mmol). The mixture was stirred at room temperature for 6 hours, then cooled in refrigeratory. After filtered, the filtrate was washed with cool citrate buffer, cool saturated NaHCO3 and cool water. The organic layer was dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by silica chromatography to give pale yellow solid (0.722 g, 93.3%). mp 140-141 C. 1HNMR (CDCl3) delta: 1.41 (9H, 2×s, 3×CH3), 2.46-2.68 (3H, m, CH2), 3.033.19 (4H, m, CH2), 3.283.49 (3H, m, CH2 and N-CH), 3.79 (3H, d, Ar-OCH3), 3.88 (3H, s, Ar-OCH3), 4.85 (1H, m, CH2), 4.98 (1H, m, COCH), 5.17 (2H, q, PhCH2), 6.63 (1H, s, ArH), 6.76 (1H, s, ArH), 6.90 (1H, s, ArH), 7.287.40 (8H, m, PhH), 7.467.48 (2H, m, PhH). MS (EI) m/z: 698 (M+), 641, 450, 434 (base), 360, 91.
93.3%	With dicyclohexyl-carbodiimide; In dichloromethane; at 20℃; for 6h;Product distribution / selectivity;	Compound HA (0.5g, l.lmmol) was dissolved in CH2Cl2 (20ml), adding t-Boc-phenylanine (0.88g, 3.3mmol) and DCC (0.91g, 4.4mmol). The mixture was stirred at room temperature for 6 hours, then cooled in refrigeratory. Afer filtered, the filtrate was washed with cool citrate buffer, cool saturated NaHCO3 and cool water. The organic layer was dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by silica chromatography to give pale yellow solid (0.722g, 93.3%). mp 140~141 C. 1HNMR (CDCl3)delta: 1.41 (9H, 2xs, 3xCH3), 2.46-2.68 (3H, m, CH2), 3.03-3.19 (4H, m, CH2), 3.28-3.49 (3H, m, CH2 and N-CH), 3.79 (3H, d, Ar-OCH3), 3.88(3H, s, Ar-OCH3), 4.85 (IH, m, CH2), 4.98 (IH, m, COCH), 5.17 (2H, q, PhCH2), 6.63 (IH, s, ArH), 6.76 (IH5 s, ArH), 6.90 (IH5 s, ArH), 7.28-7.40 (8H, m, PhH), 7.46-7.48 (2H, m, PhH). MS(EI) m/z: 698 (M+), 641, 450, 434(base), 360, 91.
24.6%		t-Boc-phenylanine (0.177g, 0.67mmol) and CDI (0.227g, 1.4mmol) was dissolved in dry THF (10ml) and stirred at room temperature for 30 minitues. Then the solution of compound HA (0.3g, 0.66mmoi) in THF (10ml) was added and stirred for one day. The mixture was evaporated under reduced pressure and purified by Al2O3 chromatography to give beige solid (0.114g, 24.6%).

Reference： [1]Patent: US2009/149488,2009,A1 .Location in patent: Page/Page column 8
[2]Patent: WO2007/6212,2007,A1 .Location in patent: Page/Page column 22
[3]Patent: WO2007/6212,2007,A1 .Location in patent: Page/Page column 22

45
[ 4530-18-1 ]
[Ru(η(5)-C5Me5)(phenylalanine methyl ester)]Cl [ No CAS ]
[ 1892-57-5 ]
[Ru(η(5)-C5Me5)(PhCH2CH(NHCOOBu(t))CONHCH(CO2H)CH2Ph)]Cl [ No CAS ]

Reference： [1]Journal of the Chemical Society, Dalton Transactions,1995,p. 1549 - 1554

46
[ 4530-18-1 ]
[ 105-54-4 ]
[ 1027818-83-2 ]

Yield	Reaction Conditions	Operation in experiment
		Starting Material 5a6-tert-Butyl 1-ethyl 4-benzyl-2-ethyl-3-oxohexanedioateAn oven dried 250 mL round bottom flask was evacuated while hot and was allowed to cool under N2. The flask was charged with anhydrous diisopropylamine (4.30 mL, 30.7 mmol) and anhydrous THF (30 mL). The solution was cooled to 0 C, and then H-BuLi (2.5 M in hexanes; 12.0 mL, 30.0 mmol) was added drop wise. The solution was allowed to stir at 0 0C for 30 min and was then cooled to -78 C. Ethyl butyrate (4.00 mL, 30.1 mmol) was added drop wise, and the solution was allowed to stir at -78 C for 1 h. Meanwhile, a separate oven- dried 100 mL round-bottom flask was evacuated while hot and was allowed to cool under N2. The flask was charged with racemic BOC-Phe-OH (2.66 g, 10.0 mmol) and 1,1'- carbonyldiimidazole (1.77 g, 10.9 mmol). The flask was evacuated and backfilled with N2, and anhydrous THF (15 mL) was added. The resulting solution was allowed to stir at room temperature for 25 min, and was then added drop wise to the cold enolate solution. This mixture was then allowed to stir at -78 C for 25 min before being quenched with glacial HOAc (3.5 mL). Upon warming, the reaction was partitioned between EtOAc and H2O and the aqueous layer was further extracted with EtOAc. The combined organics were washed with brine, dried (MgSO4), filtered, and concentrated. The crude material was purified by silica gel chromatography (gradient elution; Rf in 90:10 hexanes:EtOAc = 0.16) to give a colorless oil (2.75 g, 75%). 1H NMR is complex due to keto-enol tautomers as well as enol E/Z isomers. M/Z=363.

Reference： [1]Patent: WO2008/59238,2008,A1 .Location in patent: Page/Page column 48

47
[ 4530-18-1 ]
[ 1015068-44-6 ]
[ 1015069-87-0 ]

Yield	Reaction Conditions	Operation in experiment
78%	With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; for 3h;	B. N-({2-[(tert-Butoxy)carbonylamino]-3-phenyl-1-thioxopropyl}amino)-6-isoquinolyl carboxamide. Isoquinoline-6-carbohydrazide (100 mg, 0.5 mmol), DL N-Boc-phenylalanine (141 mg, 0.5 mmol), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU, 222 mg, 0.6 mmol), diisopropylethylamine (200 muL, 1.6 mmol), and DMF (5 mL) were added together and stirred for 3 hours. The crude reaction was added with dichloromethane and extracted with sat. NaHCO3, water, and brine in succession. The organic layer was dried over Na2SO4, filtered, and solvent was removed under reduced pressure to give an oil. The oil was flash chromatographed and eluted with 80% EtOAc-hexane. The product fractions were combined and concentrated down to give a white solid, (180 mg, 78%). MS (ESI) m/z 435.3 [M+1]+.

Reference： [1]Patent: US2008/242694,2008,A1 .Location in patent: Page/Page column 57

48
[ 4530-18-1 ]
[ 2935-90-2 ]
[ 76-05-1 ]
3-(2-amino-3-phenyl-propionylsulfanyl)-propionic acid methyl ester TFA salt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
74%		The TFA salt of a preformed [PHENYLALANINE] thioester propionic acid methyl ester [(PHE35A-COS-CH2CH2COOME)] was prepared as follows. To a stirred solution of [BOC-PHENYLALANINE] (2.65g, [10MMOL)] and HBTU (19.9 mL of a 0.5M solution in DMF, 9. [95MMOL)] in 10 mL DMF was added [DIEA] (1.28, 13.4 [MMOL).] The solution was stirred for 1 min and 3-mercapto-propionic acid methyl ester (1. [19ML,] 9.9 [MMOL)] in 5 mL DMF added in 2 min and stirred overnight. The reaction was then [CONCENTRATED IN VACUO] with co-evaporation with toluene (3 x 50 mL), taken up in ethyl acetate (100 mL). The organic layer was then washed two times with 0.25M [KHS04,] three times with 10% [NAHCO3,] five times with brine, and then water. The organic layer was then collected, dried over [NA2SO4] for 20 min, and concentrated in vacuo. The residue was analyzed by RP-HPLC (Vydac [C18,] 0-80% buffer B in 40 min) and did not require any further purification. The ammonium salt was formed by dissolution in 50% TFA in DCM for 30 min followed by repeated concentration in vacuo with DCM. The TFA. ammnonium salt of [PHENYLALANINE-ACOS-PROPIONIC] acid methyl ester was stable at 4 [C] for at least 4 weeks. ES/MS: 268 [M/Z] Da. Yield 74%.

Reference： [1]Patent: WO2004/11424,2004,A2 .Location in patent: Page 47

49
[ 4530-18-1 ]
[ 787623-15-8 ]
2-tert-butoxycarbonylamino-3-phenyl-propionic acid 5,8-dimethoxy-2,9a,10,10-tetramethyl-1,4,4a,9,9a,10-hexahydro-anthracen-1-yl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
75%		To a well-stirred solution of BOC-phenyl alanine (24 mg, 0.088 mmol) in CH2Cl2 (0.5 ml) under nitrogen atmosphere at 0 C., HOBT (24 mg, 0.175 mmol) was added followed by the addition of a solution of DCC (24 mg, 0.114 mmol) and DMAP (11 mg, 0.316 mmol) in CH2Cl2 (1 ml). The reaction mixture was stirred at 0 C. for 1 h and then at room temperature for 1 h. The reaction mixture was cooled to 0 C. and a solution of (8) (100 mg, 0.316 mmol) in CH2Cl2 (1 ml) added. The reaction mixture stirred at room temperature for 2 days. The solvent was evaporated under reduced pressure in a rotary evaporator. The residue was chromatographed over silica gel (100-200 mesh, 5% ethyl acetate in petroleum ether) to give the ester (13) (21 mg, 75% with respect to recovered starting material) as a white foamy solid.; m.p.: 66-68 C. IR(KBr): nu 3438, 2976, 1718, 1595, 1497, 1457, 1365, 1254, 1168, 1061, 795, 701 cm-1. 1H NMR(300 MHz, CDCl3): delta 0.87 (3H, s), 1.38-1.42 (15H, m), 1.55 (3H, s), 1.88 (1H, dd, J 5.55 and 11.2 Hz), 2.12-2.24 (3H, m), 3.04-3.12 (2H, m), 3.29-3.36 (1H, m) 3.68 (3H, s), 3.79 (3H, s), 4.70-4.72(1H, m), 4.96 (1H, bd, J 8.40 Hz) 5.46 (1H, bars), 5.59 (1H, bars), 6.68 (2H, 2×d, J 8.8 & 21.75 Hz), 7.16-7.29 (5H, m).

Reference： [1]Patent: US2004/220197,2004,A1 .Location in patent: Page 19-20

50
[ 4530-18-1 ]
[ 74-89-5 ]
[ 88815-83-2 ]

Yield	Reaction Conditions	Operation in experiment
99.1%	With 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide; triethylamine; In tetrahydrofuran; for 8h;	2-[(Tert-butoxycarbonyl)amino]-3-phenylpropanoic acid (500.0 mg, 1.9 mmol, 1.0 equiv) was dissolved in THF (20.0 mL). TEA (381.4 mg, 3.8 mmol, 2.0 equiv), T3P (1199.3 mg, 3.8 mmol, 2.0 equiv) and methylamine (117.1 mg, 3.8 mmol, 2.0 equiv) were added and stirred for 8 hours. The solution was concentrated under vacuum and applied onto a silica gel column with EtO Ac/PE (2: 1) as an eluent. This resulted in /-butyl N-[l- (methylcarbamoyl)-2-phenylethyl]carbamate (520 mg, 99.1%) of as a brown solid. LCMS: Method F, MS-ESI, 279.2 [M+H+]
		Scheme C, step a; Cool a solution of Boc-Phe-OH (8.00 g, 30.2 mmol) in tetrahydrofuran to -30 C. and treat sequentially with N-methylmorpholine (3.5 mL, 32 mmol) and isobutyl chloroformate (4.5 mL, 35 mmol). After 10 min, treat the reaction mixture with 40% aqueous methylamine (13 mL, 380 mmol), stir for 2 hours, and concentrate. Dissolve the residue in methylene chloride (125 mL) and wash with 1N hydrochloric acid and saturated NaHCO3 (75 mL each). Dry the organic layer (NaSO4) and concentrate to give crude title compound, which is used without further purification

Reference： [1]Patent: WO2020/10092,2020,A1 .Location in patent: Page/Page column 225; 226
[2]Patent: US6953788,2005,B1 .Location in patent: Page/Page column 77

51
[ 4530-18-1 ]
[ 118-61-6 ]
ethyl 2-(2-(tert-butoxycarbonylamino)-3-phenylpropanoyloxy)benzoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 3h;	Example 27; Preparation of ethyl 2-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido-3-phenylpropanoyloxy)benzoate (22); To a solution of ethyl 2-hydroxybenzoate (0.5 g, 3.0 mmol) in CH2Cl2 (8 mL) was added 2-(tert-butoxycarbonylamino)-3-phenylpropanoic acid (0.8 g, 3.0 mmol), EDCl (0.63 g, 3.3 mmol) and dimethylaminopyridine (0.037 g, 0.3 mmol). The reaction was stirred (RT, 3 h) and then partitioned between CH2Cl2 and brine. The aqueous layer was extracted with CH2Cl2 and the combined organic extracts were dried over MgSO4. The crude material was purified by silica chromatography (0-10% MeOH/CH2Cl2) to afford 1.2 g of ethyl 2-(2-(tert-butoxycarbonylamino)-3-phenylpropanoyloxy)benzoate. Mass calculated for C235H27NO6=413.46; found: [M+Na]+=437.1.

Reference： [1]Patent: US2010/41748,2010,A1 .Location in patent: Page/Page column 127-128

52
[ 4530-18-1 ]
[ 2491-20-5 ]
[ 1224965-70-1 ]

Reference： [1]Angewandte Chemie - International Edition,2009,vol. 48,p. 9318 - 9321

53
[ 4530-18-1 ]
[ 530-62-1 ]
[ 1224936-68-8 ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran; at 20℃; for 0.5h;	t-Boc-phenylanine (0.177 g, 0.67 mmol) and CDI (0.227 g, 1.4 mmol) was dissolved in dry THF (10 ml) and stirred at room temperature for 30 minutes. Then the solution of compound IIA (0.3 g, 0.66 mmol) in THF (10 ml) was added and stirred for one day. The mixture was evaporated under reduced pressure and purified by Al2O3 chromatography to give beige solid (0.114 g, 24.6%).
	In tetrahydrofuran; for 1h;Inert atmosphere; Reflux;	Reference Example 2:; The inventors of the present invention carried out the process for the preparation of nitroketone of formula I from N-(tert-butoxycarbonyl)-L-phenylalanine of formula II as per the method described in US Patent No. 5,599,994. The process of said prior art as practiced by the present inventors is referred to herein as a reference example. Said process carried out by the inventors of the present invention is illustrated below:; 3-N-BOC-amino-3-benzyl-2-oxo-l-nitropropane (as per US Patent No. 5,599,994): The compound, 3-N-BOC-amino-3-benzyl-2-oxo-l-nitropropane corresponds to nitroketone of formula I of the present invention.; In an argon atmosphere and under anhydrous conditions, 19.6g of 1,1'- carbonyldiimdazole (CD I) and 150ml of dry tetrahydrofuran (THF) were mixed in a reactor. 25g of BOC-phenylalanine was then added in five portions to the reactor to form a carbonyldiimidazole BOC-phenylalanine solution. Vigorous gas evolution was observed from the reaction. The mixture was refluxed for one hour and subsequently cooled to about 30C. (At this stage the reaction mixture is monitored using chiral HPLC method of analysis, the chiral purity of N-(tert- butoxycarbonyl)-L-phenylalanylimidazole of formula III is 51% and the unreacted N-(tert-butoxycarbonyl)-L-phenylalanine of formula II is 49%).In a second reactor, 13.6g of potassium tert-butoxide and 746ml of THF were mixed and then cooled in an ice bath. 7.5g of 96% nitromethane was added dropwise to the ice-cooled potassium tert-butoxide solution to form a pale yellow solution.The carbonyldiimidazole BOC-phenylalanine solution was then added dropwise to said pale yellow solution, which was concurrently cooled in an ice bath, to form a reaction mixture. After completion of the addition, the reaction mixture was allowed to stand at room temperature for 12 hours and then was refluxed for an additional 3 hours to form 3-N-BOC-amino-3-benzyl-2-oxo-l- nitropropane in solution of THF. After refluxing, the product solution was mixed with a 125ml of aqueous solution (pH＜l) containing 46.3g sulfuric acid (H2SO4) and 26.4g potassium hydroxide (KOH) to form an organic and an aqueous phase. The organic phase was concentrated to a paste, while the aqueous phase was extracted with ethyl acetate. The extracted ethyl acetate and the paste of organic phase were then combined and washed twice with aqueous potassium hydrogen sulphate (KHSO4) (final pH of the aqueous layer was 3) and then dried over anhydrous magnesium sulphate (MgS04), followed by evaporation of the filtered ethyl acetate, to obtain 92.4% of 3-N-BOC-amino-3-benzyl-2-oxo-l-nitropropane (nitroketone) as a yellow solid.Chiral purity = 50%Undesired (1R) enantiomer = 50%.Achiral Purity = 76.49%
	In tetrahydrofuran; at 20℃; for 1h;	General procedure: To a slurry of N,N'-carbonyldiimidazole (1 mmol, 162 mg) in THF (1 ml) was added a solution of benzoic acid (1 mmol, 122 mg) in THF (3 ml). The reaction mixture was stirred at room temperature for 1 h, and the resulting v solution was then concentrated to approximately 1 ml in vacuo. In a separate reaction vessel was added a solution of benzothiazole (1.2 mmol, 162 mg) in THF (1 mL) to a solution of i-PrMgCl·LiCl (1 ml, 1.3M in THF, 1.3 mmol) in THF (8 mL) over 3 min, maintaining an internal temperature at -10 C. The homogeneous solution was then stirred for 30 min. After this hold time, the (1H-imidazol-1-yl)(phenyl)methanone solution was added dropwise, and the resulting dark reddish solution was warmed to room temperature and stirred for 3 h. The reaction was quenched by addition of 13.5% NH4Cl aqueous solution (1.5 mL). The layers were mixed and then separated, and the aqueous layer was extracted with dichloromethane (3 × 10 mL). The combined organics were dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was purified by silica column chromatography to afford the product 2a as a yellow solid (215 mg, 90%).

Reference： [1]Patent: US2009/149488,2009,A1 .Location in patent: Page/Page column 8
[2]Heterocycles,2010,vol. 81,p. 611 - 623
[3]Patent: WO2011/61675,2011,A1 .Location in patent: Page/Page column 21-23
[4]Organic and Biomolecular Chemistry,2015,vol. 13,p. 10456 - 10460
[5]Tetrahedron Letters,2019,vol. 60,p. 1667 - 1670

54
[ 4556-23-4 ]
[ 4530-18-1 ]
S-pyridin-4-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanethioate [ No CAS ]

Reference： [1]Organic Letters,2010,vol. 12,p. 4716 - 4719

55
[ 4530-18-1 ]
[ 108-98-5 ]
(+/-)-2-tert-butoxycarbonylamino-3-phenyl-thiopropionic acid phenyl ester [ No CAS ]

Reference： [1]Organic Letters,2010,vol. 12,p. 4716 - 4719

56
[ 4530-18-1 ]
[ 91-59-8 ]
[ 109057-27-4 ]

Yield	Reaction Conditions	Operation in experiment
75%	With dicyclohexyl-carbodiimide; In ethyl acetate; at 20℃; for 0.166667h;	General procedure: To a solution of N-Boc protected L-phenylalanine (0.5 g, 1.8 mmol) in ethyl acetate (10 mL), 2-naphthylamine (0.30 g, 2 mmol) was added and the solution was stirred at rt for 10 min. DCC (0.43 g, 2 mmol) was then added and the reaction mixture was stirred for 2 h. The precipitate formed was filtered and washed twice with ethyl acetate. The filtrate was washed with a saturated solution of KHSO4 and then with brine solution. The organic layer was dried over Na2SO4, filtered and evaporated. The solid obtained was then purified by column chromatography with hexane:EtOAc (70:30) to give 0.53 g (75 %) of 4a as a white solid.

Reference： [1]Tetrahedron Letters,2012,vol. 53,p. 5745 - 5748

57
[ 4530-18-1 ]
[ 28955-70-6 ]
C₂₁H₂₂N₂O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
38%	With dmap; dicyclohexyl-carbodiimide; In tetrahydrofuran; at 20℃;	General procedure: To a solution of 4-hydroxy-2(3H)-benzoxazolone (2, 0.66 mmol) in THF, N,N2-dicyclohexylcardodiimide (DCC, 0.66 mmol), 4-dimethylaminopyridine (DMAP, 0.13 mmol), and R-carboxylic acid or benzoic acid (0.79 mmol) were added. The mixture was stirred at room temperature until the starting material was consumed (monitored by TLC). The residue obtained after removal of the solvent under reduced pressure was purified by silica gel column chromatography using ethyl acetate/petroleum benzene (1:4-2:3).

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 2380 - 2383

58
[ 4530-18-1 ]
[ 145149-48-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 989 - 994
[2]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 192 - 202

59
[ 4530-18-1 ]
[ 89238-99-3 ]
[ 126686-59-7 ]

Yield	Reaction Conditions	Operation in experiment
89%	In dichloromethane; at 20℃; for 24h;Inert atmosphere;	The carboxylic acid (1.50 mmol) was dissolved in anhydrous CH2Cl2 (6 mL, to provide a 0.25M solution). 4-Methoxybenzyl-2,2,2-trichloroacetimidate (430 mg, 3.00 mmol, 2.0 equiv) was then added. After 24 hTLC indicated that all of the starting material had been consumed. The reaction mixture was taken up inethyl acetate and washed with sodium bicarbonate (sat. aq., 3x). The organic layer was dried (Na2SO4),filtered and concentrated. The residue was adsorbed on silica gel and purified by silica gelchromatography to provide the corresponding PMB ester.

Reference： [1]Tetrahedron Letters,2014,vol. 55,p. 1740 - 1742
[2]Journal of Organic Chemistry,2019,vol. 84,p. 7871 - 7882

60
[ 4530-18-1 ]
ethyl rac-(2S,4S,5S)-5-(benzo[d][1,3]dioxol-5-yl)-4-cyano-4-methylpyrrolidine-2-carboxylate [ No CAS ]
C₃₀H₃₅N₃O₇ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		To a solution of N-Boc-phenylalanine (263 mg, 1.00 mmol, 1.5 equiv) in dry CH2C12 (2 mL) at 0 C was added N,N-diisopropylethylamine (0.12 mL, 0.66 mmol, 1 equiv) and BOPC1 (253 mg, 1.00 mmol, 1.5 equiv) and the reaction was allowed to warm to room temperature over 1 h. After recooling to 0 C additional N,N-diisopropylethylamine (0.23 mL, 1.3 mmol, 2 equiv) was added, followed by the dropwise addition of a solution of the corresponding pyrrolidine ester (200 mg, 0.66 mmol, 1 equiv) in CH2C12 (1.3 mL). The reaction was allowed to warm to room temperature overnight, after which time TLC analysis showed full conversion of the starting material. After an extractive work-up (CH2Cl2/water), the crude product was filtered through a silica gel plug using hexanes/ethyl acetate (1 : 1) as the eluent and the volatiles were removed in vacuo. The crude acylated pyrrolidine ester was dissolved in dry CH2C12 (2.1 mL) and cooled to 0 C. Trifluoroacetic acid (0.8 mL) was added, the reaction allowed to warm to rt over 3 h, and the volatiles were removed under reduced pressure. The resulting residue was dissolved in a 4: 1 mixture z-BuOH/toluene (18 mL) containing N,N-diisopropylethylamine (0.46 mL, 2.65 mmol, 4 equiv). The vial was sealed with a teflon cap and heated to 100 C overnight. After an extractive work up (CH2Cl2/water) and concentration, two diastereomeric DKPs were separated by silica gel chromatography (eluent: hexanes/EtOAc 1 :3).[0513] NMR data for diastereomer A: 1H-NMR (600 MHz, CDC13) delta 7.38-7.35 (m, 3H), 7.26- 7.25 (m, 2H), 7.00 (d, J= 3.7 Hz, 1H), 6.78 (d, J= 8.0 Hz, 1H), 6.63 (d, J= 7.2 Hz, 1H), 6.55 (s, 1H), 5.92 (s, 2H), 4.71 (s, 1H), 4.29 (app. q, J= 4.2 Hz, 1H), 3.31 (dd, J= 13.9, 4.6 Hz, 1H), 2.95 (dd, J= 13.9, 4.4 Hz, 1H), 2.64 (dd, J= 11.9, 6.2 Hz, 1H), 2.44 (app. t, J= 12.5 Hz, 1H), 2.05 (dd, J= 13.0, 6.3 Hz, 1H), 1.32 (s, 3H) ppm. NMR data for diastereomer B: 1H-NMR (600 MHz, CDC13) delta 7.37-7.34 (m, 2H), 7.32-7.29 (m, 1H), 7.22-7.19 (m, 2H), 6.81 (d, J= 8.0 Hz, 1H), 6.64 (dd, J= 8.8, 1.7 Hz, 1H), 6.60 (d, J= 1.8 Hz, 1H), 6.00 (d, J= 1.5 Hz, 1H), 5.99 (d, J = 1.5 Hz, 1H), 5.69 (broad s, 1H), 4.91 (s, 1H), 4.40 (dd, J= 11.3, 6.9 Hz, 1H), 4.32 (dd, J = 10.2, 4.2 Hz, 1H), 3.51 (dd, J= 14.7, 3.9 Hz, 1H), 2.79 (dd, J= 11.5, 4.1 Hz, 1H), 2.77 (dd, J = 10.3, 4.4 Hz, 1H), 2.40 (dd, J= 13.4, 6.8 Hz, 1H), 1.68 (s, 3H) ppm

Reference： [1]Patent: WO2014/66435,2014,A1 .Location in patent: Paragraph 0510-0513

61
[ 4530-18-1 ]
[ 94298-51-8 ]
C₃₀H₃₀N₂O₅ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
65%	With 2-(diacetoxyiodo)mesitylene; palladium diacetate; In acetonitrile; at 80℃; for 24h;Inert atmosphere;	General procedure: A mixture of N-methyl-N,3-diphenylpropiolamide 1a (0.3mmol), Boc-NHCH2CO2H2a (1.5 mmol), Pd(OAc)2 (5 mol %) and MesI(OAc)2 (0.4 mmol) in CH3CN (2 mL)was stirred at 80 oC for the indicated time until complete consumption of startingmaterial as monitored by TLC. After the reaction was finished, the mixture waspoured into ethyl acetate, which was washed with brine. The aqueous layer wasfurther extracted with ethyl acetate. The combined organic layers was dried overanhydrous Na2SO4 and evaporated under vacuum. The residue was purified by flashcolumn chromatography (hexane/ethyl acetate) to afford the desired product 3a

Reference： [1]Synthetic Communications,2014,vol. 44,p. 689 - 696

62
[ 4530-18-1 ]
[ 28144-70-9 ]
[ 1206450-66-9 ]

Yield	Reaction Conditions	Operation in experiment
97%		General procedure: 2-[N-(tert-Butoxycarbonyl)amino]methyl}quinazolin-4-(3H)-ones 3a-d; General ProcedureA solution of i-BuO2CCl (11 mmol) in THF (10 mL) was added dropwiseto a solution of the appropriate N-(tert-butoxycarbonyl)aminoacid (11 mmol) and NMM (11 mmol) in THF (30 mL) at -15 C underN2, and the mixture was stirred for 1 h. A soln of 2-aminobenzamide(10 mmol) in THF (15 mL) was added dropwise, and the mixture wasstirred at r.t., then refluxed for 10 h. The mixture was cooled and thena 30% soln of NaOMe in MeOH (20 mmol) and MeOH (20 mL) wereadded. The the mixture was refluxed for 3 h then cooled and concentratedunder reduced pressure to give a residue that was dissolved inH2O (50 mL). The pH was adjusted to 3 with 10% aq oxalic acid (10mL) and the resulting precipitate was collected by filtration, washedwith H2O (2 × 10 mL), and recrystallized from EtOH.

Reference： [1]Synthesis,2015,vol. 47,p. 377 - 386

63
[ 4530-18-1 ]
[ 593284-22-1 ]
C₃₂H₃₅N₃O₅ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
76%	With dicyclohexyl-carbodiimide; In dichloromethane; at -5 - 20℃; for 7.75h;	General procedure: To a solution of 29.4 mg (0.1 mmol) N-1',8'-naphthaloyl-(R,R)-1,2-diaminocyclohexane (1a)25 and 0.1 mmol appropriate N-Boc amino acid in dichloromethane (7 mL) at -5C was added DCC (20.6 mg, 0.1 mmol). The mixture was stirred in an ice bath (0 to -5C) for 45 min and stirring was continued for additional 7 h at room temperature. The precipitated N,N-dicyclohexylurea was filtered and the filtrate evaporated to dryness. The crude product was dissolved in diethyl ether to precipitate a further amountof N,N'-dicyclohexylurea. The product was then purified by extraction with dichloromethane and 1 N HCl, followedby washing with saturated NaHCO3 solution, drying over MgSO4 and evaporation. D-Ala-1c. Yield 68%; m.p. 175-1788C; 1H NMR d 0.79(d, J 5 7.14 Hz, 3H), 1.04-1.91 (m, 6H), 1.32 (s, 9H), 2.14-2.18 (m, 1H), 2.80 (ddd, J 5 5.1, 7.1, 13.1 Hz, 1H), 3.81-3.89 (m, 1H), 4.88-5.03 (m, 3H), 5.68 (d, J 5 8.2 Hz, 1H),7.73 (bs, 2H), 8.19 (d, J 5 8.2 Hz, 2H), 8.54-8.61 (m, 2H).

Reference： [1]Chirality,2008,vol. 20,p. 301 - 306

64
[ 4530-18-1 ]
[ 97682-44-5 ]
camptothecin [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 2690 - 2693

65
[ 4530-18-1 ]
1-Phenylethynyl-1H-1λ³-benzo[d][1,2]iodoxol-3-one [ No CAS ]
tert-butyl (1,4-diphenylbut-3-yn-2-yl)carbamate [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2016,vol. 81,p. 12357 - 12363
[2]Angewandte Chemie - International Edition,2015,vol. 54,p. 11196 - 11199
Angew. Chem.,2015,vol. 127,p. 11348 - 11351,4

66
[ 4530-18-1 ]
[ 378-44-9 ]
C₃₆H₄₆FNO₈ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
18%	With dmap; In dichloromethane; N,N-dimethyl-formamide; at 0 - 20℃;	2.03 g of Boc-phenylalanine was dissolved in 20 mL of dichloromethane and 20 mL of dimethyl formamide followed by addition of 3 g of betamethasone. After cooling to 0 C., 280.2 mg of N,N-dimethylaminopyridine and 1.91 g of water soluble carbodiimide were added followed by stirring overnight at room temperature. After confirming by thin layer chromatography the disappearance of the reacting materials, a saturated aqueous solution of ammonium chloride was added to terminate the reaction. Liquid fractionation extraction was performed by using toluene and water, and the organic layer was washed with a saturated aqueous solution of ammonium chloride, a saturated aqueous solution of sodium hydrogen carbonate, and saturated brine. After drying over magnesium sulfate anhydrous and filtering, the solvent was distilled off under reduced pressure to obtain the desired compound 19 (0.837 g, 18%).

Reference： [1]Patent: US2016/158369,2016,A1 .Location in patent: Paragraph 0226

67
[ 4530-18-1 ]
2-(chloromethoxy)-1-[(1R)-1-cyclopropylethyl]-3-isopropyl-benzene [ No CAS ]
[2-[(1R)-1-cyclopropylethyl]-6-isopropyl-phenoxy]methyl(2S)-2-(tert-butoxycarbonylamino)-3-phenylpropanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
77.6%	With triethylamine; In acetonitrile; at 60℃; for 2h;	2-(chloromethoxy)-1-[(1R)-1-cyclopropylethyl]-3-isopropylbenzene(32B) (0.253 g, 1 mmol), 3(tertbutoxycarbonylamino)propanoic acid(0.584 g, 2.2 mmol) and triethylamine (0.3 mL, 2.2 mmol) was dissolved in acetonitrile (5 mL), the mixture was stirred at 60 C. for 2 h, and wasconcentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v)=80:1) to obtain [2-[(1R)-1-cyclopropylethyl]-6-isopropyl-phenoxy]methyl(2S)-2-(tertbutoxycarbonylamino)-3-phenylpropanoate(Compound 61) as a colorlessliquid (0.374 g, yield: 77.6%).

Reference： [1]Patent: KR2016/5361,2016,A .Location in patent: Paragraph 1275-1281

68
[ 4530-18-1 ]
C₄₈H₅₄N₆O₄ [ No CAS ]
C₆₂H₇₁N₇O₇ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With dicyclohexyl-carbodiimide; In dichloromethane; at -15 - 20℃; for 48h;	(2-4) Step (2-2) and step (2-3) was repeated to the step (2-1) system to connect four units of phenylalanine on the product. Boc protected phenylalanine was used alternative to Boc protected phenylalanine dipeptide and step (2-2) and step (2-3) was repeated to the step (2-1) system to connect five units of phenylalanine on the product.

Reference： [1]Patent: CN105837587,2016,A .Location in patent: Paragraph 0142; 0194; 0195

69
[ 4530-18-1 ]
2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide [ No CAS ]
C₃₄H₃₄N₄O₉S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: Boc-Gly (350 mg, 2 mmol), DCC (384 mg, 2 mmol) and HOBt(270 mg, 2 mmol) were mixed in dichloromethane (30 mL) with amagnetic stirrer for 5 min at RT, and to this mixture was slowlyadded a solution of 12c (427 mg, 1 mmol) in dichloromethane(30 mL). After stirred for 12H at RT, the reaction mixture wasfiltered and the liquid layer was washed with water (3 15 mL),dried over anhydrous sodium sulfate, concentrated under reducedpressure. The oily residue was dissolved in DCM (20 mL) at RT, andinto this mixture was added trifluoroacetic acid (7 mL) with amagnetic stirrer for 2H at RT. Then the mixture was filtered and theresidue was washed sequentially with ethanol (2 10 mL) anddichloromethane (15 5 mL) to afford 13a as a pale yellowamorphous solid (224 mg, 43% yield).

Reference： [1]European Journal of Medicinal Chemistry,2017,vol. 129,p. 310 - 324

70
[ 4530-18-1 ]
[ 5747-48-8 ]
tert-butyl 1-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-ylcarbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
82%	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 12h;Inert atmosphere;	Compound 12(20.00 gm, 67.71 mmol), Boc protected Phenyl alanine (19.75 gm, 74.46 mmol),TBTU (32.61 gm, 101.57 mmol), DMF (200 mL, 10 Vol) and DIPEA (26.25 gm, 203.13mmol) were taken in a round bottom flask at room temperature under nitrogenatmosphere. The reaction was stirred for 12 hours at the same temperature and then monitored by TLC. After completion of thestarting material the reaction mixture was diluted with water (600 mL) andstirred for 1 hour at room temperature. The solids were filtered and washedwith water (100 mL x 2) and then dried under vacuum at 50 C to yield 30 gof Compound13 (Yield 82%) as an off-white solid. Offwhite solid; m.p. 120-124 C; 1H NMR (400 MHz, DMSO-d6): delta 7.54-7.56(d, 1H, J=8.0 Hz), 7.42-7.47 (m,4Hz), 7.17-7.25 (m, 7H), 6.98-7.00 (d, 1H, J=8.0Hz), 6.88-6.92 (1H, t, J=7.6 Hz),4.58-4.60 (d, 1H, J=7.2 Hz),3.44-3.82 (m, 6H), 3.11-3.19 (bs, 1H), 2.75-2.90 (m, 3H) and 1.30 (s, 9H); Massm/z = 543 (M+H)+.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 4140 - 4145

71
[ 4530-18-1 ]
[ 524-38-9 ]
1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate [ No CAS ]

Reference： [1]Organic Letters,2018,vol. 20,p. 4579 - 4583
[2]Angewandte Chemie - International Edition,2017,vol. 56,p. 11649 - 11652
Angew. Chem.,2017,vol. 129,p. 11808 - 11811,4
[3]Organic Letters,2019,vol. 21,p. 5728 - 5732
[4]Angewandte Chemie - International Edition,2019,vol. 58,p. 12081 - 12085
Angew. Chem.,2019,vol. 131,p. 12209 - 12213,5
[5]Chemical Communications,2020,vol. 56,p. 2495 - 2498

72
[ 4530-18-1 ]
[ 54-85-3 ]
C₂₀H₂₄N₄O₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In chloroform; at 0 - 20℃;	General procedure: A mixture of Boc-protected amino acid (4mmol) and HOBt (0.62g, 4mmol) in CHCl3 was stirred and cooled to 0C (ice bath). Then, antibacterial drugs (1-3) (4mmol) triethylamine (4mmol) and EDC (4mmol) were added. The mixture was allowed to warm to room temperature and stirring continued overnight. The mixture was diluted with CHCI3 and washed with 1N HC1 (thoroughly), aq. sat. NaHCO3 and NaCl solution. The organic phase was dried MgSO4 and evaporated. The crude residues were purified by column chromatography using n-hexane/ethyl acetate resulted in 71-80% yield.

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 145,p. 140 - 153

73
[ 4530-18-1 ]
[ 3638-04-8 ]
[ 21253-58-7 ]
C₃₁H₃₆N₈O₈ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran;	General procedure: In the first step mono-substituted triazine (13) was synthesized by using following procedure. A solution of triazine (12, 2mmol) and K2CO3 (4mmol) was stirred in anhydrous THF at 0C under nitrogen. Antimicrobial drugs (1-3) were then added drop-wise and the reaction mixture was allowed to warm at room temperature. The progress of the reaction was monitored by TLC. After the completion of the first step, a solution of N-Boc protected amino acids (8-10) in THF were added drop-wise. After the completion of reaction the mixture, the crude residues were purified by column chromatography using n-hexane/ethyl acetate. In the final step the di-substituted product was de-protected by using procedure described in section 4.2

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 145,p. 140 - 153

74
[ 4530-18-1 ]
[ 738-70-5 ]
C₂₈H₃₅N₅O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In chloroform; at 0 - 20℃;	General procedure: A mixture of Boc-protected amino acid (4mmol) and HOBt (0.62g, 4mmol) in CHCl3 was stirred and cooled to 0C (ice bath). Then, antibacterial drugs (1-3) (4mmol) triethylamine (4mmol) and EDC (4mmol) were added. The mixture was allowed to warm to room temperature and stirring continued overnight. The mixture was diluted with CHCI3 and washed with 1N HC1 (thoroughly), aq. sat. NaHCO3 and NaCl solution. The organic phase was dried MgSO4 and evaporated. The crude residues were purified by column chromatography using n-hexane/ethyl acetate resulted in 71-80% yield.

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 145,p. 140 - 153

75
[ 4530-18-1 ]
[ 30575-42-9 ]
C₂₀H₂₆N₄O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In N,N-dimethyl-formamide; at 75 - 80℃;	General procedure: In the second step, a mixture of MTZ-OTs i.e. 5mmol and DHPM carbohydrazides (5mmol) was dissolved in 20mL of DMF as a solvent) and K2CO3 (8mmol) was added in round bottom flask, and stirred at 75-80C. The reaction condition was monitored by TLC. After completion of the reaction, the reaction mixture was poured into ice and extracted with chloroform. The organic layer was separated and dried over anhydrous sodium sulphate. Finally, the product was purified by using silica gel chromatography (CHCl3-MeOH).

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 145,p. 140 - 153

76
[ 4530-18-1 ]
[ 62-53-3 ]
[ 19901-55-4 ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; dicyclohexyl-carbodiimide; In dichloromethane; at 50℃; for 10h;	(1) Aniline (0.93g, 0.0 lmo 1) was added to a 250ml round bottom flask, and a small amount of methylene chloride was added for stirring to dissolve while the temperature was set to 50 C. After the aniline was sufficiently miscible, N-Boc benzene Alanine (2.79g, 0.lOmol), and then added condensing agent DCC (2.06g, 0.01mol), DMAP catalyst (0.61g, 0.005mol); until all the raw materials and then add all the additional dichloromethane, The total volume is 18 0m 1.(After the reaction for 10 hours, the reaction solution was spin-dried, the sample was mixed with silica gel, dry method on the column, the use of thin layer chromatography twice point plate until the intermediate product point Rf value of 0.1 ~ 0.8, and then column Separation, eluent dichloromethane / methanol (methanol / dichloromethane volume ratio of 0: 100 ~ 50: 50), to obtain an intermediate product.

Reference： [1]Patent: CN107673988,2018,A .Location in patent: Paragraph 0068-0070

77
[ 4530-18-1 ]
[ 62-53-3 ]
C₂₀H₂₄N₂O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; dicyclohexyl-carbodiimide; In dichloromethane; at 50℃; for 10h;	(1) In a 250 ml round bottom flask, aniline (0.93 g, 0.01 mol) was added, and a small amount of methylene chloride was added to stir and dissolve while the temperature was set to 50C;After the aniline was fully miscible, N-Boc phenylalanine (2.79 g, 0.01 mol) was added followed by the condensing agent DCC (2.06 g, 0.01 mol), DMAP catalyst (0.61 g, 0.005 mol).After all the raw materials are added, add methylene chloride to make the total volume 180 ml; (2) After the reaction is completed for 10 hours, the reacted solution is spin-dried, and the mixture is mixed with silica gel. The column is dry-processed and the plate is spotted twice by thin-layer chromatography.After the Rf value of the intermediate product point was determined to be 0.1 to 0.8, the column was separated and the eluent was dichloromethane/methanol (volume ratio of methanol/dichloromethane was 0:100 to 50:50) to obtain an intermediate product.

Reference： [1]Patent: CN107759486,2018,A .Location in patent: Paragraph 0049; 0050; 0071; 0072

78
[ 4530-18-1 ]
[ 108-45-2 ]
C₃₄H₄₂N₄O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; dicyclohexyl-carbodiimide; In dichloromethane; at 50℃; for 6h;	In a similar manner as in Example 1, the pH of the solution after addition of the base was changed. In a 250 ml round bottom flask,M-phenylenediamine (1.08g, 0.01mol), it was added a small amount of methylene chloride and stirred to dissolve while the temperature is set to 50 . After the meta-phenylenediamine was completely dissolved, N-Boc phenylalanine (5.30 g, 0.02 mol) was added followed by the condensing agent DCC (4.12 g, 0.02 mol), DMAP catalyst (0.61 g, 0.005 mol). After all the ingredients were added, methylene chloride was added to make the total volume 180 ml. After 6 hours of reaction, the reacted solution was spin-dried and mixed with silica gel. The column was dry-processed and the plate was spotted twice by TLC until the Rf value of the intermediate product point was determined. Then the column separation was performed. The eluent was Methanol/dichloromethane (volume ratio of methanol/dichloromethane 0:100 to 50:50) gives an intermediate product. After the obtained intermediate product A was weighed, strong acid trifluoroacetic acid was metered in (the amount of strong acid was added in the range of 0.4-2 ml per gram of intermediate product), and the reaction time was 1 h. After the reaction was completed, the solution was spin-dried, and water was added to sufficiently stir and dissolve the solution. Insoluble matter was removed by vacuum extraction. The insoluble material was generally a yellow oil. Then, the alkaline solution was added to the reaction solution, and the pH after the addition of alkali was 10. Alkali was found after the white material was precipitated, vacuum filtration after freezing, the filter residue was drained to obtain the target product. The structural characterization is shown in Figures 1, 2, and 3. Yellow sticky material, yield 96%.

Reference： [1]Patent: CN107840806,2018,A .Location in patent: Paragraph 0017; 0049-0050

79
[ 150322-38-6 ]
[ 4530-18-1 ]
5-(2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl 2-((tert-butoxy-carbonyl)amino)-3-phenylpropanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 4h;	General procedure: EDCI (1.2 g, 6 mmol) was slowly added to an ice-cooled mixture o f3a (1.0 g, 3 mmol), L-N-Boc-alanine (0.7 g, 3.6 mmol), DMAP (40 mg, 0.3 mmol) in DCM (15 mL).The mixture was gradually warmed to room temperature and stirred for additional 4.0 h until the completion of the reaction detected by TLC. Then it was poured into ice-water (500 mL). The organic was separated and the aqueous was extracted with DCM. The combined organic was successively washed with cold 1.0 M aq HCl, saturated aq Na2CO3, and brine.

Reference： [1]Molecules,2018,vol. 23

80
[ 4530-18-1 ]
(SR)-methyl 2-(2-chlorophenyl)-2-(2-oxo-7,7a-dihydrothieno-[3,2-c]pyridin-5(2H,4H,6H)-yl)acetate [ No CAS ]
5-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl 2-((tert-butoxy-carbonyl)amino)-3-phenylpropanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 4h;	General procedure: EDCI (1.2 g, 6 mmol) was slowly added to an ice-cooled mixture o f3a (1.0 g, 3 mmol), L-N-Boc-alanine (0.7 g, 3.6 mmol), DMAP (40 mg, 0.3 mmol) in DCM (15 mL).The mixture was gradually warmed to room temperature and stirred for additional 4.0 h until the completion of the reaction detected by TLC. Then it was poured into ice-water (500 mL). The organic was separated and the aqueous was extracted with DCM. The combined organic was successively washed with cold 1.0 M aq HCl, saturated aq Na2CO3, and brine.

Reference： [1]Molecules,2018,vol. 23

81
[ 4530-18-1 ]
[ 107-14-2 ]
[ 19901-51-0 ]

Yield	Reaction Conditions	Operation in experiment
96%	With triethylamine; In N,N-dimethyl-formamide; at 0 - 20℃; for 2h;	To a solution of (tert-butoxycarbonyl)-phenylalanine (13) (1 g, 3.77 mmol) in DMF (20 mL) and TEA (1.05 mL, 7.54 mmol) at 0 C was added chloroacetonitrile (0.24 mL, 3.77 mmol). It was stirred at room temperature for 2h. Reaction was quenched with ice and compound was extracted with etyhlacetate (4 x 25 mL). Combined organic layer was washed with brine (50 mL), dried over sodium sulphate and concentrated under vacuum to achieve crude product. It was later purified by Column chromatography (eluted with 20-25% EtOAc in Hexanes) to achieve white solids of cyanomethyl (tertbutoxycarbonyl)-phenylalaninate (1a) (1.1 g, 3.61 mmol, 96 % yield). 1H NMR (400 MHz, DMSO-d6): delta 7.48 (d, J = 7.6 Hz, 1H), 7.34-7.21 (m, 5H), 5.00 (s, 2H), 4.30-4.20 (m, 1H), 3.00-2.92 (m, 1H), 3.90-2.82 (m, 1H), 1.30 (s, 9H). MS (ESI): 322.3 as [M+H2O]+ in +Ve mode.

Reference： [1]Tetrahedron Letters,2018,p. 4267 - 4271

82
[ 4530-18-1 ]
[ 5217-47-0 ]
tert-butyl [1-(1,3-diethyl-4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)-1-oxo-3-phenylpropan-2-yl]carbamate [ No CAS ]

Reference： [1]Acta Crystallographica Section C: Structural Chemistry,2018,vol. 74,p. 1703 - 1714

83
[ 4530-18-1 ]
[ 135415-73-5 ]
C₃₀H₂₅N₃O₇*(x)ClH [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
77%		Add BOC to protect phenylalanine (10 mmol) and chloroform (20 mL) in a 25 mL round bottom flask, stir and dissolve at 25 C, add EDCI (10 mmol), stir at 0.5 C for 0.5 h.Then add DMAP (50 mg) and stir at 25 C for 0.5 h.Finally, FL118 (3 mmol) was added, and the reaction was stirred at 25 C for 3 hours to obtain a pale yellow suspension. After the reaction was completed, chloroform (40 mL) was added to the reaction mixture, and the mixture was filtered with suction The organic solution was washed with sodium sulfate, dried over anhydrous magnesium sulfate, filtered, filtered, and evaporated to dryness, and the filtrate was concentrated to silica gel column chromatography, eluting with a mixture of dichloromethane and methanol at a volume ratio of 100:1. The eluate containing the target component is concentrated and dried, and the reaction product is dissolved in 25 ml of organic solvent methanol. The color of the reaction liquid changes under the action of hydrogen chloride gas, and the reaction is stopped by TLC for 40 minutes until the reaction is no longer carried out. After work-up in a liquid, the reaction mixture was dried in vacuo and then evaporated and evaporated.That is, FL118 phenylalanine hydrochloride derivative was obtained in a yield of 77%.

Reference： [1]Patent: CN108822120,2018,A .Location in patent: Paragraph 0064-0067

84
[ 623-26-7 ]
[ 4530-18-1 ]
[ 1004983-82-7 ]

Reference： [1]Organic Letters,2019,vol. 21,p. 2130 - 2133

85
[ 4530-18-1 ]
7-fluoro-4-(1-piperazinyl)quinoline [ No CAS ]
C₂₇H₃₁FN₄O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In chloroform; at 20℃; for 8h;	General procedure: Glycine (150 mg, 2 mmol), in a solution of THF (30mL), H2O (20 mL) and NaOH (1 mol/L, 20 mL) was stirredat 0-5 for 15 min. The reaction mixture was treated with (Boc)2O (0.87 g, 4 mmol) at room temperature for overnight. The organic solvent was removed under reduced pressure. The residue was extracted by ether (50.0 mL×2). The water phase was adjusted with 1.0 mol/L HCl to pH 2-3 and then extracted with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous MgSO4 and concentrated under reduced pressure to afford N-Boc-Glycine (319.50 mg, yield 91.1%). The reaction of N-Boc-Glycine (143.65 mg, 0.82 mmol) with compound 2 (0.1 g,0.42 mmol) in the presence of EDC·HCl (0.243 g, 1.3 mmol) and Et3N (263 mg, 2.6 mmol) in CHCl3 (15mL) for 8h yielded the corresponding compound III1 (139.07 mg,85.3%). Compound III1 (139.07 mg, 0.36 mmol) was hydrolyzed using TFA (6.79 mmol) in CH2Cl2 (20 mL) at room temperature for 48h. The reaction mixture was alkalized to pH= 10 with anhydrous Na2CO3, and the CH2Cl2 layer was washed to pH 6-7 with distilled water and concentrated to dryness. The crude product was purified by column chromatography (silica gel, CHCl3-MeOH (50:1,v/v)) to give target compound IV1 as a white solid (24.66mg, yield 21.2%) Yield: 25.0%

Reference： [1]Letters in drug design and discovery,2019,vol. 16,p. 663 - 669

86
[ 4530-18-1 ]
C₂₃H₃₃NO₆ [ No CAS ]
C₃₇H₅₀N₂O₉ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
9 g	With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 12h;	Add SZY-1805-6 (10.0) to a 250ml round bottom flask,Add 50 ml of dichloromethane to dissolve. SZY-1805-7e (6g), DMAP (0.2g), EDCI (5g) were added in this order, and the reaction was stirred at room temperature for 12h.The reaction was monitored by TLC. The DCM was removed by rotary evaporation under reduced pressure, 150 ml of EA was added, and 150 ml of water were separated.Wash twice with 100 ml of organic phase water and twice with 100 ml of saturated saline.It was dried over anhydrous sodium sulfate and filtered to obtain 9.0 g of oil (SZY-1805-8e).

Reference： [1]Patent: CN110526885,2019,A .Location in patent: Paragraph 0046; 0106-0108

87
[ 4530-18-1 ]
[ 137-07-5 ]
tert-butyl [1-(1,3-benzothiazol-2-yl)-2-phenylethyl]carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	With iodine; at 20℃; for 0.333333h;	General procedure: The reaction between protected amino acid (500 mg, 2.7 mmol) and 2-aminothiophenol (0.67 mL, 5.3 mmol) in the presence of iodine (223 mg, 1.8 mmol) as a catalyst was carried out following the procedure described in [14]. The reaction was complete (TLC monitoring) in 20 min. The product was washed with aqueous Na2S2O3 to removeunreacted iodine and purified by recrystallization from a 70 : 30 ethanol-water mixture.

Reference： [1]Russian Journal of Organic Chemistry,2020,vol. 56,p. 292 - 297

88
[ 4530-18-1 ]
14-amino-tetrandrine [ No CAS ]
14-(2-(N-(tert-butoxycarbonyl)amino)-3-phenylpropanamido)tetrandrine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
85%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃;Inert atmosphere;	General procedure: To a mixture of Tet-NH2 (100 mg, 0.16 mmol), HOBT (8.47 mg, 0.63 mmol), EDCI (27.3 mg,0.17 mmol) and Boc-l-amino acid (0.17 mmol, 1.1 eq) was added DCM (2.0 mL) under the protection ofargon atmosphere, and stirred at room temperature for 1.5 to 3 h. The reaction mixture was quenched with saturated aqueous solution of sodium bicarbonate, extracted with DCM (3 10 mL), dried overanhydrous sodium sulfate and filtered. The solvent was removed under reduced pressure, and theresidue was purified by silica gel chromatography eluated with DCM/MeOH (40/1 v/v, 0.5% TEA) toaord compounds 1a-1k.14-((R)-2-(N-(tert-butoxycarbonyl)amino)-3-phenylpropanamido)tetrandrine (1a). White to light yellowamorphous solid, yield: 85%. Mp: 136-137 C. 1H-NMR (600 MHz, CDCl3) 12.20 (s, 1H), 7.58 (s, 1H),7.36-7.29 (m, 5H), 7.26 (t, J = 7.2 Hz, 1H), 7.23 (dd, J = 7.8, 2.4 Hz, 1H), 6.63 (dd, J = 8.4, 2.4 Hz, 1H), 6.57(s, 1H), 6.49 (s, 1H), 6.32 (s, 1H), 6.16 (dd, J = 8.4, 1.8 Hz, 1H), 5.91 (s, 1H), 5.44 (d, J = 12.0 Hz, 1H), 4.47(m, 1H), 3.94 (d, J = 9.0 Hz, 4H), 3.83 (dd, J = 10.8, 5.4 Hz, 1H), 3.76 (s, 3H), 3.58 (m, 1H), 3.47 (m, 1H),3.36 (s, 3H), 3.27 (m, 2H), 3.16-3.08 (m, 5H), 3.01-2.88 (m, 4H), 2.79 (t, J = 12.0 Hz, 1H), 2.70 (dd, J = 16.2,5.4 Hz, 1H), 2.62 (s, 3H), 2.49 (dd, J = 17.4, 4.2 Hz, 1H), 2.40 (d, J = 17.4 Hz, 4H), 1.46 (s, 9H). 13C-NMR(150 MHz, CDCl3) 169.2, 155.8, 155.2, 152.2, 149.4, 148.6, 148.1, 145.6, 144.2, 138.2, 136.6, 134.2, 132.9,131.5, 129.7, 129.6, 128.6, 128.5, 127.8, 127.2, 127.0, 125.8, 121.4, 121.1, 121.1, 120.8, 120.6, 112.3, 106.9,105.8, 79.6, 77.3, 77.1, 76.8, 64.2, 61.4, 60.1, 56.3, 56.2, 55.8, 55.6, 53.4, 45.1, 43.2, 42.5, 40.7, 40.0, 39.6, 38.9,29.7, 28.4, 24.8, 20.7. HRMS (ESI) calcd. for C52H61N4O9: 885.4429 [M + H]+, found 885.4433.

Reference： [1]Molecules,2020,vol. 25

Same Skeleton Products

Related Products

Historical Records

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 4530-18-1 ] {[proInfo.proName]}

Quality Control of [ 4530-18-1 ]

Related Doc. of [ 4530-18-1 ]

Product Details of [ 4530-18-1 ]

Calculated chemistry of [ 4530-18-1 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 4530-18-1 ]

Application In Synthesis of [ 4530-18-1 ]

[ 4530-18-1 ] Synthesis Path-Upstream 1~11

[ 4530-18-1 ] Synthesis Path-Downstream 1~88

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry